Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

Prior treatment

• Current or previous long-term immune suppressive therapy. Systemic steroid use, even short-term, must not have been used within the month prior to enrollment.
• Long term use of anticoagulant or antiplatelet medications.
• Active participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study.
• Use of medications with a high-risk for withdrawal-related complications (i.e. long-acting opiates or benzodiazepines).

Other illness

• Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.
• Current systemic immunologic disorders (e.g. Type 1 diabetes, rheumatoid arthritis). Local immunological disorder (e.g. atopic dermatitis, stable autoimmune thyroid disease) and allergic disorders will be allowed.

Other

• Current suicidal ideation
• Women who are pregnant, breastfeeding, or are within one-year post-partum.
• Not willing to allow for research data and samples to be shared broadly with other researchers.
• Employees of NIH.
• Symptom severity that makes it impossible for the volunteer to travel to NIH for an extended inpatient evaluation
• Unwillingness to co-enroll in protocol 17-I-0122: NIAID Centralized Sequencing Protocol.

• Participants 18 and older
• Ability to provide informed consent
• Completed participation in Phase B of Protocol 000089
• Met 000089 Inclusion criteria for Mild to Moderate COVID-19 without PASC symptoms:
  • Licensed Independent Practitioner documentation of a stable state of general well-health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.
  • A self-reported illness narrative of recovery to prior health after a SARS/CoV2 infection.
  • Laboratory documentation of a positive COVID-19 PCR, NAA, or other EUA Approved test to confirm active COVID infection at the time of the SARS-CoV-2 infection. Participants with positive home tests during Phase A will be required to have a positive anti-SARS nucleocapsid antibody test.
  • Meets WHO Clinical Progression Scale of 2 - 6:
  • 2: Ambulatory; symptomatic, independent
  • 3: Ambulatory; symptomatic, assistance needed
  • 4: Hospitalized; no oxygen therapy
  • 5: Hospitalized; oxygen by mask or nasal prongs
  • 6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen
  • Functional Criteria: No substantial symptom severity as determined using SF-36v2: score of \>=85 physical function subscale, and \>=85 on role physical subscale, and \>=85 on social function subscale.
• Determined to be a Healthy Comparator by the 000089 Case Adjudication Committee
• Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-2 infection. This may include screening interviews and/or testing. Testing may be repeated with each admission. Participants may be rescreened 6 weeks after acute infection has resolved.
  • Neurologic Post-Acute Sequelae of COVID-19 Participants (Neuro-PASC):
  • Six persons with ongoing neurological complaints following an acute SARS-CoV-2 infection.
• Participants 18 and older
• Ability to provide informed consent
• Completed participation in Phase B of Protocol 000089
• Met 000089 Inclusion criteria for Mild to Moderate COVID-19 with PASC symptoms:
  • Licensed Independent Practitioner documentation of a stable state of general well-health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.
  • A self-reported illness narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, unrefreshing sleep, neuropathic pain, mood change, and post-exertional malaise.
  • Laboratory documentation of a positive COVID-19 PCR, NAA, or other EUA Approved test to confirm active COVID infection at the time of the SARS-CoV-2 infection. Participants with positive home tests during Phase A will be required to have a positive anti-SARS nucleocapsid antibody test .
  • Meets WHO Clinical Progression Scale of 2 - 6:
  • 2: Ambulatory; symptomatic, independent
  • 3: Ambulatory; symptomatic, assistance needed
  • 4: Hospitalized; no oxygen therapy
  • 5: Hospitalized; oxygen by mask or nasal prongs
  • 6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen
  • Functional Criteria: Substantial symptom severity as determined using SF-36v2: score of \<= 70 physical function subscale, or \<=50 on role physical subscale, or \<=75 on social function subscale.
• Determined to have Post-Acute Sequelae of COVID-19 by the 000089 Case Adjudication Committee
• Primary PASC complaint is neurologic including:
  • Neuropathic sensations
  • Cognitive complaints
  • Postural (Orthostatic) complaints
  • Motor complaints
• Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-2 infection. This may include screening interviews and/or testing. Testing may be repeated with each admission. Participants may be rescreened 6 weeks after acute infection has resolved.

Criteria the registry did not label

• INCLUSION CRITERIA:
  • Recovered Volunteers (RV): Six healthy persons who have recovered from an acute SARS-CoV-2 infection.